| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 35 | 2025 | 248 | 5.530 |
Why?
|
| Genetic Predisposition to Disease | 29 | 2025 | 372 | 5.420 |
Why?
|
| Polymorphism, Single Nucleotide | 32 | 2025 | 363 | 4.460 |
Why?
|
| Genetic Loci | 11 | 2022 | 54 | 3.470 |
Why?
|
| Glaucoma, Open-Angle | 6 | 2024 | 8 | 3.240 |
Why?
|
| Cataract | 4 | 2025 | 12 | 2.670 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 5 | 2020 | 5 | 2.490 |
Why?
|
| Glaucoma | 6 | 2024 | 11 | 2.310 |
Why?
|
| Myopia | 5 | 2024 | 10 | 2.020 |
Why?
|
| Skin Neoplasms | 4 | 2024 | 58 | 1.760 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 56 | 1.610 |
Why?
|
| Humans | 70 | 2025 | 17314 | 1.610 |
Why?
|
| Migraine Disorders | 2 | 2023 | 17 | 1.510 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2024 | 24 | 1.490 |
Why?
|
| European Continental Ancestry Group | 15 | 2021 | 476 | 1.470 |
Why?
|
| Ethnic Groups | 6 | 2021 | 451 | 1.350 |
Why?
|
| Intraocular Pressure | 6 | 2024 | 10 | 1.330 |
Why?
|
| Hispanic Americans | 8 | 2021 | 375 | 1.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 13 | 2023 | 664 | 1.190 |
Why?
|
| Alcohol Drinking | 6 | 2022 | 356 | 1.150 |
Why?
|
| Male | 39 | 2025 | 9804 | 1.080 |
Why?
|
| Female | 41 | 2025 | 12396 | 1.040 |
Why?
|
| Mutation | 8 | 2020 | 132 | 1.030 |
Why?
|
| Brain | 3 | 2016 | 48 | 1.020 |
Why?
|
| Middle Aged | 31 | 2025 | 7836 | 0.970 |
Why?
|
| African Americans | 6 | 2021 | 439 | 0.970 |
Why?
|
| Eye Proteins | 1 | 2025 | 16 | 0.950 |
Why?
|
| Refractive Errors | 2 | 2022 | 7 | 0.950 |
Why?
|
| Aged | 25 | 2025 | 6084 | 0.910 |
Why?
|
| Meta-Analysis as Topic | 2 | 2021 | 31 | 0.880 |
Why?
|
| Mutation, Missense | 4 | 2020 | 21 | 0.850 |
Why?
|
| Adult | 30 | 2023 | 7500 | 0.850 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2020 | 5 | 0.830 |
Why?
|
| DNA Glycosylases | 1 | 2023 | 5 | 0.830 |
Why?
|
| Genotype | 12 | 2020 | 223 | 0.780 |
Why?
|
| Obesity | 9 | 2013 | 814 | 0.770 |
Why?
|
| Smoking | 4 | 2025 | 429 | 0.770 |
Why?
|
| Vaping | 4 | 2021 | 19 | 0.750 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 4 | 0.700 |
Why?
|
| Cannabis | 2 | 2021 | 85 | 0.700 |
Why?
|
| Mendelian Randomization Analysis | 5 | 2025 | 26 | 0.680 |
Why?
|
| Cornea | 1 | 2020 | 3 | 0.670 |
Why?
|
| Corneal Diseases | 1 | 2020 | 3 | 0.670 |
Why?
|
| Keratinocytes | 1 | 2020 | 5 | 0.670 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 20 | 0.660 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2016 | 32 | 0.660 |
Why?
|
| Genes, Modifier | 1 | 2020 | 2 | 0.650 |
Why?
|
| Drug Administration Routes | 1 | 2019 | 5 | 0.640 |
Why?
|
| Risk Factors | 13 | 2025 | 3258 | 0.630 |
Why?
|
| Phenotype | 9 | 2021 | 149 | 0.630 |
Why?
|
| Cohort Studies | 9 | 2024 | 2514 | 0.610 |
Why?
|
| Proprotein Convertase 1 | 3 | 2013 | 3 | 0.590 |
Why?
|
| Electronic Nicotine Delivery Systems | 3 | 2021 | 29 | 0.570 |
Why?
|
| Cerebral Hemorrhage | 2 | 2014 | 12 | 0.560 |
Why?
|
| Genetic Variation | 6 | 2022 | 77 | 0.550 |
Why?
|
| Quantitative Trait Loci | 6 | 2024 | 38 | 0.540 |
Why?
|
| Alcoholism | 2 | 2020 | 337 | 0.540 |
Why?
|
| CD36 Antigens | 2 | 2019 | 2 | 0.510 |
Why?
|
| Matrix Metalloproteinases | 1 | 2016 | 4 | 0.500 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2016 | 7 | 0.490 |
Why?
|
| Oxidative Stress | 1 | 2016 | 11 | 0.490 |
Why?
|
| Prenatal Care | 3 | 2020 | 127 | 0.490 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 1 | 0.470 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2020 | 535 | 0.460 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2020 | 87 | 0.450 |
Why?
|
| Animals | 6 | 2024 | 280 | 0.440 |
Why?
|
| Inflammation | 1 | 2014 | 63 | 0.440 |
Why?
|
| Point Mutation | 1 | 2013 | 6 | 0.430 |
Why?
|
| Macular Degeneration | 2 | 2024 | 20 | 0.430 |
Why?
|
| Lens, Crystalline | 2 | 2025 | 3 | 0.420 |
Why?
|
| Trabecular Meshwork | 2 | 2024 | 2 | 0.410 |
Why?
|
| Receptors, Nicotinic | 1 | 2013 | 7 | 0.410 |
Why?
|
| Self Report | 3 | 2020 | 257 | 0.410 |
Why?
|
| TCF Transcription Factors | 6 | 2008 | 9 | 0.400 |
Why?
|
| Multifactorial Inheritance | 3 | 2022 | 21 | 0.400 |
Why?
|
| Mice | 4 | 2024 | 80 | 0.400 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 22 | 0.400 |
Why?
|
| Adolescent | 10 | 2021 | 3538 | 0.390 |
Why?
|
| Dermatitis, Atopic | 2 | 2023 | 16 | 0.390 |
Why?
|
| Alcohol-Related Disorders | 1 | 2013 | 48 | 0.380 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 22 | 0.360 |
Why?
|
| Young Adult | 6 | 2020 | 2465 | 0.360 |
Why?
|
| Child | 9 | 2023 | 2403 | 0.350 |
Why?
|
| Protein Precursors | 1 | 2011 | 4 | 0.350 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 437 | 0.350 |
Why?
|
| KRIT1 Protein | 3 | 2016 | 3 | 0.350 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 32 | 0.350 |
Why?
|
| Sex Factors | 3 | 2021 | 603 | 0.340 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 33 | 0.340 |
Why?
|
| Case-Control Studies | 10 | 2021 | 1098 | 0.330 |
Why?
|
| Haplotypes | 2 | 2024 | 34 | 0.330 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 1925 | 0.330 |
Why?
|
| Prevalence | 4 | 2021 | 840 | 0.330 |
Why?
|
| Transcription Factors | 2 | 2021 | 19 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 102 | 0.330 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2009 | 28 | 0.310 |
Why?
|
| Alleles | 5 | 2020 | 80 | 0.300 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 532 | 0.290 |
Why?
|
| Body Mass Index | 6 | 2018 | 937 | 0.290 |
Why?
|
| Pregnant Women | 3 | 2020 | 46 | 0.280 |
Why?
|
| Substance-Related Disorders | 3 | 2021 | 425 | 0.270 |
Why?
|
| Pregnancy | 5 | 2025 | 1463 | 0.270 |
Why?
|
| Transcriptome | 2 | 2023 | 25 | 0.250 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 22 | 0.250 |
Why?
|
| United Kingdom | 3 | 2024 | 25 | 0.250 |
Why?
|
| Strabismus | 1 | 2025 | 1 | 0.240 |
Why?
|
| beta-Crystallin B Chain | 1 | 2025 | 2 | 0.240 |
Why?
|
| Twins, Dizygotic | 1 | 2015 | 7 | 0.230 |
Why?
|
| Twins, Monozygotic | 1 | 2015 | 11 | 0.230 |
Why?
|
| Underage Drinking | 1 | 2015 | 6 | 0.230 |
Why?
|
| Social Behavior | 1 | 2015 | 21 | 0.230 |
Why?
|
| Collagen | 2 | 2024 | 8 | 0.230 |
Why?
|
| Cytoskeleton | 1 | 2024 | 1 | 0.230 |
Why?
|
| Ocular Hypertension | 1 | 2024 | 1 | 0.230 |
Why?
|
| Attitude | 1 | 2015 | 28 | 0.230 |
Why?
|
| Septins | 1 | 2024 | 2 | 0.230 |
Why?
|
| Multigene Family | 2 | 2016 | 6 | 0.230 |
Why?
|
| Mice, Knockout | 2 | 2021 | 14 | 0.230 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2021 | 19 | 0.220 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2024 | 1 | 0.220 |
Why?
|
| California | 4 | 2020 | 2311 | 0.210 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 10 | 0.210 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2023 | 3 | 0.210 |
Why?
|
| Nicotine | 2 | 2021 | 27 | 0.210 |
Why?
|
| DNA Repair Enzymes | 1 | 2023 | 6 | 0.210 |
Why?
|
| France | 8 | 2010 | 11 | 0.210 |
Why?
|
| Biomarkers | 2 | 2021 | 307 | 0.210 |
Why?
|
| Proteins | 2 | 2024 | 15 | 0.200 |
Why?
|
| Genotyping Techniques | 2 | 2020 | 26 | 0.200 |
Why?
|
| Membrane Proteins | 1 | 2023 | 38 | 0.200 |
Why?
|
| Mental Disorders | 1 | 2016 | 274 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2021 | 5 | 0.200 |
Why?
|
| Internationality | 1 | 2022 | 13 | 0.200 |
Why?
|
| Polymorphism, Genetic | 3 | 2014 | 62 | 0.200 |
Why?
|
| Tobacco Use | 1 | 2022 | 14 | 0.200 |
Why?
|
| Europe | 4 | 2022 | 46 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 20 | 0.190 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 5 | 0.190 |
Why?
|
| Dementia | 1 | 2024 | 121 | 0.190 |
Why?
|
| Heterozygote | 3 | 2019 | 26 | 0.190 |
Why?
|
| Prognosis | 2 | 2021 | 603 | 0.190 |
Why?
|
| Leukocytes | 1 | 2021 | 11 | 0.180 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 18 | 0.180 |
Why?
|
| Ribonucleoproteins | 1 | 2021 | 1 | 0.180 |
Why?
|
| Caspase 7 | 1 | 2021 | 1 | 0.180 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 30 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2021 | 8 | 0.180 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 7 | 2009 | 11 | 0.180 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 44 | 0.180 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 1 | 0.180 |
Why?
|
| Keratoconus | 1 | 2021 | 1 | 0.180 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2020 | 5 | 0.180 |
Why?
|
| Genetic Background | 1 | 2020 | 2 | 0.170 |
Why?
|
| Skin Pigmentation | 1 | 2020 | 6 | 0.170 |
Why?
|
| Adipose Tissue | 3 | 2012 | 65 | 0.170 |
Why?
|
| Asian Americans | 1 | 2021 | 163 | 0.170 |
Why?
|
| United States | 4 | 2021 | 3866 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1280 | 0.170 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 19 | 0.170 |
Why?
|
| Age of Onset | 2 | 2015 | 70 | 0.160 |
Why?
|
| beta-Globins | 1 | 2019 | 1 | 0.160 |
Why?
|
| Aging | 1 | 2021 | 160 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 3 | 0.160 |
Why?
|
| Tonometry, Ocular | 1 | 2019 | 2 | 0.160 |
Why?
|
| Skin Cream | 1 | 2019 | 3 | 0.160 |
Why?
|
| Plants, Edible | 1 | 2019 | 6 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2019 | 29 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 195 | 0.160 |
Why?
|
| Dyslipidemias | 1 | 2019 | 56 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 52 | 0.150 |
Why?
|
| Logistic Models | 1 | 2021 | 879 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 211 | 0.150 |
Why?
|
| Coronary Disease | 1 | 2019 | 146 | 0.150 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 36 | 0.150 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2018 | 2 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 3 | 0.150 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 5 | 0.150 |
Why?
|
| Retinal Ganglion Cells | 1 | 2018 | 5 | 0.150 |
Why?
|
| Counseling | 1 | 2020 | 174 | 0.150 |
Why?
|
| Gene Expression | 1 | 2018 | 23 | 0.150 |
Why?
|
| Asthma | 1 | 2021 | 400 | 0.140 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 4 | 0.140 |
Why?
|
| Documentation | 1 | 2017 | 40 | 0.140 |
Why?
|
| HEK293 Cells | 3 | 2021 | 9 | 0.130 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2013 | 7 | 0.120 |
Why?
|
| Genome, Human | 2 | 2021 | 34 | 0.120 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2014 | 1 | 0.120 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 2 | 0.120 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2014 | 2 | 0.120 |
Why?
|
| Genes, MHC Class II | 1 | 2014 | 2 | 0.110 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2014 | 3 | 0.110 |
Why?
|
| Insulin | 3 | 2012 | 188 | 0.110 |
Why?
|
| Interleukin-4 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Mexico | 1 | 2013 | 18 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 2 | 0.090 |
Why?
|
| Pedigree | 2 | 2009 | 63 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2017 | 704 | 0.090 |
Why?
|
| Finland | 1 | 2010 | 1 | 0.090 |
Why?
|
| Germany | 1 | 2010 | 13 | 0.090 |
Why?
|
| Pregnancy, Unwanted | 1 | 2020 | 7 | 0.090 |
Why?
|
| Intention | 1 | 2020 | 30 | 0.080 |
Why?
|
| Computational Biology | 2 | 2020 | 26 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 1282 | 0.080 |
Why?
|
| Cation Transport Proteins | 1 | 2010 | 2 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2010 | 11 | 0.080 |
Why?
|
| Linkage Disequilibrium | 2 | 2020 | 28 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2018 | 2415 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1151 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 2 | 2006 | 18 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2019 | 39 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2008 | 3 | 0.070 |
Why?
|
| Insulin Resistance | 4 | 2012 | 128 | 0.070 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2007 | 54 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2020 | 34 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2021 | 1076 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2018 | 154 | 0.060 |
Why?
|
| Glucose | 3 | 2012 | 31 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 118 | 0.060 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 7 | 0.060 |
Why?
|
| Multilevel Analysis | 1 | 2015 | 11 | 0.060 |
Why?
|
| Actomyosin | 1 | 2024 | 1 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2024 | 1 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2024 | 2 | 0.060 |
Why?
|
| High-Temperature Requirement A Serine Peptidase 1 | 1 | 2024 | 1 | 0.060 |
Why?
|
| Complement Factor H | 1 | 2024 | 2 | 0.060 |
Why?
|
| Environment | 1 | 2015 | 50 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2024 | 11 | 0.060 |
Why?
|
| Linear Models | 1 | 2015 | 206 | 0.060 |
Why?
|
| Social Environment | 1 | 2015 | 85 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 3 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2024 | 15 | 0.060 |
Why?
|
| Visual Acuity | 1 | 2024 | 18 | 0.060 |
Why?
|
| Transcription Factor 4 | 1 | 2024 | 1 | 0.050 |
Why?
|
| Laminin | 1 | 2024 | 2 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 49 | 0.050 |
Why?
|
| Risk | 2 | 2019 | 496 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2023 | 2 | 0.050 |
Why?
|
| Sample Size | 1 | 2022 | 26 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 674 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2022 | 1 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 7 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2022 | 15 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2008 | 640 | 0.050 |
Why?
|
| Proteome | 1 | 2021 | 2 | 0.050 |
Why?
|
| Aqueous Humor | 1 | 2021 | 1 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 35 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 1 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2021 | 2 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 41 | 0.040 |
Why?
|
| Australia | 1 | 2021 | 25 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 20 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 4 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 37 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2020 | 1 | 0.040 |
Why?
|
| Genetics | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 9 | 0.040 |
Why?
|
| Ethanol | 1 | 2020 | 21 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 357 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2019 | 8 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2019 | 6 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 12 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 177 | 0.040 |
Why?
|
| Tobacco | 1 | 2019 | 11 | 0.040 |
Why?
|
| Patient Participation | 1 | 2020 | 119 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 605 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2020 | 197 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 203 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2009 | 314 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2017 | 60 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 672 | 0.030 |
Why?
|
| Incidence | 2 | 2008 | 1266 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2012 | 1 | 0.020 |
Why?
|
| Lipogenesis | 1 | 2012 | 1 | 0.020 |
Why?
|
| Adipocytes | 1 | 2012 | 4 | 0.020 |
Why?
|
| Adipogenesis | 1 | 2012 | 4 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Exons | 1 | 2012 | 8 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2012 | 6 | 0.020 |
Why?
|
| Diet, High-Fat | 1 | 2012 | 5 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 19 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 9 | 0.020 |
Why?
|
| Glycosylation | 1 | 2011 | 2 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 34 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2012 | 48 | 0.020 |
Why?
|
| Glucose Intolerance | 1 | 2012 | 43 | 0.020 |
Why?
|
| Zinc Transporter 8 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Glucagon | 1 | 2010 | 1 | 0.020 |
Why?
|
| Arginine | 1 | 2010 | 12 | 0.020 |
Why?
|
| Glyburide | 1 | 2010 | 7 | 0.020 |
Why?
|
| Tunisia | 1 | 2009 | 1 | 0.020 |
Why?
|
| Ideal Body Weight | 1 | 2009 | 10 | 0.020 |
Why?
|
| tRNA Methyltransferases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 23 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2008 | 3 | 0.020 |
Why?
|
| Homeostasis | 1 | 2008 | 11 | 0.020 |
Why?
|
| Fasting | 1 | 2008 | 46 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 342 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 560 | 0.020 |
Why?
|
| Overweight | 1 | 2009 | 266 | 0.020 |
Why?
|
| Rats | 1 | 2006 | 35 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2007 | 170 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 701 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2007 | 805 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 1161 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 1380 | 0.010 |
Why?
|